![]() ![]() Researchers have developed GD2 targeting antibodies which work by targeting GD2 receptor on cancer cells. Owing to its restricted expression in normal cells, targeting GD2 has proven to be effective for the treatment of cancer. Genomic analysis of neuroblastoma has revealed high expression of GD2 on cancer cells. The treatment with conventional cancer therapies are associated with poor survival outcomes, thus posing high medical needs for the development of targeted therapies. Neuroblastoma is an embryonic cancer of the post-ganglionic sympathetic nervous system. DUBLIN, November 19, 2021-( BUSINESS WIRE)-The "Unituxin Patent, Sales & Clinical Trials Outlook 2028" report has been added to 's offering. ![]()
0 Comments
Leave a Reply. |